Five-year outcomes of transcatheter aortic valve implantation with the ACURATE neo2 valve system

In the ACURATE neo AS study, the ACURATE neo2 valve (Boston Scientific) demonstrated good clinical outcomes in patients with severe aortic stenosis (AS), with significant improvement in valve haemodynamics up to 12 months, including a low overall rate of paravalvular leak (97% had mild or less at 30 days; 97.5% had mild or less at 1 year)1. Here, we evaluate the 5-year clinical outcomes from the ACURATE neo AS study. An evolution of the ACURATE neo valve, the ACURATE neo2 is a transcatheter heart valve (THV) system that retains key design features from its predecessor: the self-expanding nitinol frame with axial, self-aligning stabilisation arches, and supra-annular porcine pericardium leaflets. The integrated internal and external porcine pericardium sealing skirts have been updated to further reduce paravalvular leak (Figure 1A).

ACURATE neo AS is a prospective, multicentre single-arm clinical study. Patients were enrolled at 9 European centres between December 2016 and November 2017. The primary endpoint of the study, the incidence of all-cause mortality at 30 days, was 3.3%1. Clinical events as defined per Valve Academic Research Consortium (VARC)-2...